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Cephalexin 
in V i t ro a n d in V i v o Studies 
Frank Cox, Jr., M.D.; Edward L. Quinn, M.D.; Bienvenido G. Gatmaitan, M.E., 
and Nancy Peterson, B.A.* 
Cephalexin, a derivative of cephalosporin C, produces high serum and urine con-
centrations after oral administration. In addition, it shows good activity in vitro 
against most gram-positive and some gram-negative organisms. This study reports 
the in vitro susceptibility to cephalexin of a series of clinical isolates, the serum 
levels and urine concentrations in human volunteers and the results of its use in 
infections due to susceptible organisms. Results of in vitro susceptibility testing re-
veal that cephalexin was effective against most strains of the gram-positive organ-
isms tested — group A streptococci, pneumococci, and staphylococci — although 
the MIC's are higher than those found for cephaloridine and ampicillin, with the 
one exception being penicillinase producing staphylococcus against which ampicillin 
is ineffective. Cephalexin is effective against most strains of indole-negative proteus, 
Klebsiella and E. coli, but all strains of enterobacter show resistance. Forty-seven 
patients with a variety of clinical illnesses were treated with cephalexin. Five of 14 
patients with urinary tract infections were cured and nine had a remission followed 
by a bacteriologic relapse. All patients with soft tissue infection were cured as were 
nine of 12 patients with pneumonia. Of the three patients with pneumonia who 
were not cured, one improved, while two were classified as treatment failures. 
Similarly, 11 of 12 patients with streptococcal pharyngitis had a clinical remission, 
although in three, the organism was isolated after therapy. One patient with 
an associated coagulase-positive staphylococci cultured from the pharynx failed 
to respond to treatment. 
Of the antibiotics derived from 
cephalosporin C, cephalothin and 
cephalordine have proven useful in the 
treatment of a variety of infections 
caused by most gram-positive and some 
gram-negative organisms. Both are 
poorly absorbed from the gastrointes-
tinal tract and must be employed par-
enterally only. Another derivative of 
cephalosporin C, cephaloglycin, was 
absorbed when administered orally, but 
serum levels were inadequate for the 
treatment of most organisms which are 
susceptible in vitro to moderate levels 
of the drug, although urine levels were 
considerably higher and satisfactory re-
sults were obtained in the treatment of 
* Division of Infectious Diseases, Depart-
ment of Medicine 
in-inary tract infections due to suscepti-
ble organisms.^  - Recently, cephalexin 
(7[Da = amino-aphenylacetamide]-3-
methyl-cephem-4-carboxylic acid) was 
shown to produce high serum levels 
after oral administration. We, therefore 
undertook to study the in vitro suscepti-
bility to cephalexin of a series of clini-
cal isolates; the serum levels and urine 
concentrations in human volunteers; 
and, its efficacy in infections due to sus-
ceptible organisms. The result of these 
studies forms the basis for this report. 
Materials and Methods 
The organisms used for susceptibility 
testing were isolated from patients at the 
Henry Ford Hospital and stored on 
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agar slants under sterile mineral oil. 
Minimal inhibitory concentration 
(MIC) for the 257 clinical isolates was 
determined in trypticase soy broth by 
the standard two-fold dilution method* 
using a IO* dilution of an 18-hour 
broth cultiure. 
Senun levels and urinary excretion 
were determined in 10 healthy adult 
volunteers given 250 mg and 500 mg of 
cephalexin orally. Venous blood was 
drawn at 1, 2, 4, and 6 hoiu-s after in-
gestion of the cephalexin and all mine 
was collected over the six-hour period. 
The sera and urine levels were deter-
mined by the cup-plate method using 
Sarcina lutea as the test organism.* 
Protein binding was determined by 
a parallel two-fold dilution method 
which has been described in a previous 
publication.'* 
Cephalexin was administered to 47 
patients with a variety of infections 
caused by susceptible gram-positive 
and gram-negative organisms. Doses 
ranged from 1 to 2 grams per day in 
four equal doses and the treatment 
course ranged from 7 to 14 days. 
Results 
Ninety-one strains of E. coli were 
tested, and the results are listed in 
Figiure 1. Ninety-three percent of 
strains of E. coli were susceptible to 
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6.2 meg or less of cephaloridine, 80% 
to 6.2 meg or less of ampicillin, and, 
while only 28% were susceptible to 6.2 
meg or less of cephalexin, 95% were 
inhibited by 25 meg or less. For cepha-
loridine and ampicillin at this level, the 
figures are 99% and 91% respectively. 
Thirty-nine strains of Klebsiella were 
tested and more than 90% were in-
hibited by 12.5 meg or less of both 
cephalexin and cephaloridine while 
only 8% were susceptible to 12.5 meg 
or less of ampicillin. In contrast, all 18 
strains of Enterobacter studied were re-
sistant to more than 25 meg of all three 
agents. 
The results with 35 strains of pro-
teus species are shown in Figure 2. 
Twenty-three were indole negative and 
12 indole positive. For the indole 
negative strains, ampicillin was most 
potent with 100% of strains inhibited 
by 6.2 meg per ml. Cephaloridine in-
hibited all strains at a concentration of 
12.5 meg or less. Cephalexin showed 
comparable activity though 8% of 
strains required 50 mcg/ml for inhibi-
tion. Al l 12 strains of indole positive 
Proteus proved resistant to more than 
50 mcg/ml of all three antibiotics. 
The results for staphylococci are 
shown in Figure 3. Al l strains of non-
penicillinase producing staphylococci 
were highly susceptible to ampicillin 
(0.2 mcg/ml or less) while none of the 
penicillinase producing strains were in-
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hibited by less than 25 mcg/ml. Both 
groups were inhibited by low levels of 
cephaloridine, but were less susceptible 
to cephalexin. For the penicillinase pro-
ducing strains, the MICs ranged from 
0.2 to 12.5 mcg/ml while of the non-
penicillinase producing strains 75% 
were inhibited by 12.5 mcg/ml or less, 
97% by 25 mcg/ml and 3% (one 
strain) was resistant to more than 50 
mcg/ml. 
Susceptibility of the other pathogenic 
gram-positive organisms is shown in 
Figure 4. Both the Pneumococcus and 
Group A streptococcus were inhibited 
by low levels of ampicillin and cepha-
loridine, while somewhat higher levels 
of cephalexin were required. Eighty 
percent of pneumococcal strains were 
sensitive to 1.5 meg or less of cepha-
lexin and all were inhibited by 6.2 
mcg/ml. The sensitivities to cephalexin 
of the Group A streptococci fell be-
tween 0.1 and 1.5 mcg/ml. 
Serum levels and urinary excretion 
of cephalexin were studied in normal 
adult volunteers. These were compared 
to the values obtained by Bunn and co-
workers' for ampiciUin and values for 
cephaloridine obtained previously in 
this laboratory.* The mean serum con-
centrations after a single oral dose of 
250 mg of cephalexin are shown in 
Table I . Peak levels of cephalexin oc-
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TABLE \. Serum Concentrations and Urinary Excretion After 
Single 250 mg. Dose 
Ampiciliin* Cephaioridine" Cepiialexin 
(Oral) (I.M.) (Oral) 
meg./mi. meg./mi. meg./ml. 
1/2 
--
9.2 5.7 
1 tir. 1.6 10. 5 10.9 
2hr. 2.0 5.5 4.9 
4hr. L6 2.0 1.0 
6 1lr. 
~ -
<0.6 
6 tir. Urinary 
Excretion {%of 25.0% 60.4% 100.0% 
administered dose) 
• After Bunn 151 
" After Lane, et al (4) 
curred at one hour and the levels at one 
and two hours are quite comparable 
to those observed with intramuscular 
cephaloridine. In contrast, the peak 
level of ampicillin was considerably 
lower, although at four hours similar 
levels were observed with all three. 
Urinary excretion amounted to 60% 
and 100% of the administered dose of 
cephaloridine and cephalexin respec-
tively. Urinary excretion of ampicillin 
is 30%-40% of an administered dose. 
95 
Cox, Quinn, Gatmaitan and Peterson 
In Table I I , the resuhs with the 500 
mg dose are shown. Al l levels were 
higher, and again the relative relation-
ship among the three antibiotics was 
maintained. 
Protein binding of the three anti-
biotics was assayed by the method of 
determining the relative efficacy of 
each in broth medium as compared to 
serum. Ampicillin was 25% bound to 
serum protein, cephalexin 40%, and 
cephaloridine was not bound to any ap-
preciable degree. 
Clinical Studies 
The efficacy of cephalexin was evalu-
ated in 47 patients with a variety of 
clinical illnesses. Five patients were 
excluded from consideration because 
of incomplete data. 
In Table I I I , the results of treatment 
in 14 patients with urinary tract 
infections who received two grams of 
cephalexin per day for seven days are 
shown. Five were cleared of bacteri-
uria, and their urine remained sterile 
over a six-week period. These are clas-
sified as cured. Nine of the patients ex-
perienced a satisfactory remission of 
their symptoms, while under treatment, 
and their urine was rendered free of 
bacteria. These nine patients showed 
bacteriological relapse, however, dur-
ing the six-week followup period. 
Five patients with soft tissue infec-
tion caused by Group A beta hemolytic 
streptococci, coagulase positive staphy-
lococci, or both were treated with from 
1-2 grams of cephalexin daily and all 
were cured, as noted in Table IV. 
Table V depicts the results in 12 
patients with pneumonia who were 
treated with two grams of cephalexin 
daily for seven days; nine were classi-
TABLE II. Serum Concentrations and Urinary Excretion After 
Single 500 mg. Dose 
Ampicillin' Cephaloridine" Cepiialexin 
(Oral) (I.M.I (Oral) 
meg. /ml. meg. /mi. meg./ml. 
1/2 iir. 
-
11.2 10.8 
1 tir. 3.3 15.6 21.2 
2 tir. 3.7 10.8 10.1 
4 tir. 1.6 4.6 2.6 
6 tir. a. 8 
— 
0.7 
6 tir. Urinary 
Excretion (%of 25.0% 68.5% 100.0% 
administered dose) 
• After Bunn (5) 
" After Lane, et al (4) 
TABLE III. Clinical Results of Patients Treated witti Ceptiaiexin 
Cured Improved Failed 
Urinary Tract Infection 
Acute 
Klebsiella 1 
E. Coli 2* 
Proteus /Vtirabilis 
E. Coli and Proteus 
IVlirabilis 
Ctironic 
^ Coil I 
Klebsiella 
Proteus Mirabilis and 
Enterococcus 
Asymptomatic 
E. Coli 
Klebsiella and 
Enterococcus 1 
One patient tiad initial IV Keflin 
TABLE IV. Clinical Results of Patients Treated with Cephalexin 
Soft Tissue Infection 
Beta Hemolytic 
Streptocxeus (Group A) 
Staphylxoccus 
(Coagulase Positive) 
Beta Hemolytic 
Streptococcus (Group Al 
and 
Staphylococcus 
(Coagulase Positive) 
Cured Improved Failed 
1 
2 
TABLE V. Clinical Results of Patients Treated with Cephalexin 
Cured Improved Failed 
Pneumonia 
Pneumococcus 4 1 
with bacteremia 1 1 
Hemophilus parainfluenza 1 
E. Coli with bacteremia 1 
Undetermined 3 
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TABLE VI. Clinical Results of Patients Treated with Cephalexin 
Pharyngitis 
Beta Hemolytic Streptococcus 
Group A 
Non Group A 
Plus staphylococcus (Coagulase Positive) 
Peritonsillar Abscess 
Beta Hemolytic Streptococcus 
(Group A) 
Acute Pharyngitis and 
Sinusitis 
Beta Hemolytic Streptococcus (Group A) 
Cured Improved Failed 
fied as cured; one improved, with two 
failures. One patient with pneumococ-
cal pneumonia improved clinically, but 
pneumococci of the same group were 
isolated from the sputum during and 
after the course of treatment. One pa-
tient with E. coli pneumonia and bac-
teremia was cured; however, another 
with pneumonia caused by H. influen-
zae failed. 
Twelve patients with pharyngitis due 
to both Group A and nonGroup A 
beta hemolytic streptococci were 
treated with one gram of cephalexin for 
10 days. It can be seen in Table V I 
that eight were cured and three had re-
mission of symptoms, although the or-
ganism could still be cuhured from the 
pharynx. One patient had an associated 
coagulase positive staphylococcal infec-
tion and failed to respond. 
No major reactions to cephalexin 
were observed. One patient who had 
received ampicillin prior to the cepha-
lexin experienced mild diarrhea, but 
was able to complete the course of 
cephalexin. 
Discussion 
The place of the currendy available 
cephalosporin derivatives in the treat-
ment of susceptible infections, particu-
larly in patients who are allergic to 
penicillin, is clearly established. The use 
of cephalosporins has been limited by 
the necessity to employ them parenter-
ally. Cephalexin administered orally 
was shown to produce serum levels that 
approached those attained with paren-
teral cephaloridine, while cephalexin's 
in vitro efficacy against the common 
gram-positive pathogens, such as 
Group A streptococci, pneumococci, 
and staphylococci, was less than cepha-
loridine on a mg for mg basis. None-
theless, the serum level necessary for 
inhibitions of these organisms was weU 
within the achievable range for cepha-
lexin. For the susceptible gram-negative 
organisms, E. coli, Klebsiella, and Pro-
teus mirabilis, cephalexin was almost as 
potent as cephaloridine. The high levels 
of urinary excretion of cephalexin sug-
gested that it would be useful in the 
treatment of urinary tract infections 
caused by susceptible organisms. Lewi-
son and co-workers* reported 23 pa-
tients with urinary tract infections 
treated with cephalexin; all became 
abacteriuric within 72 hours of initia-
tion of treatment, and 10 remained 
free of infections for at least two 
months after treatment was discontin-
ued. Our results are similar in the 14 
patients with urinary tract infections. 
All became abacteriuric while on treat-
ment and five remained clear for six 
weeks after cessation of cephalexin. 
In our patients with pneumonia, 
three of 11 had a suboptimal result. 
This may be due to marginal serum 
drug levels. An increased dose of 
cephalexin might yield better results. 
The same may apply to four of 12 
pharngidites, three exhibited a satisfac-
tory clinical response, although the 
organism could still be cultured during 
treatment. In the fourth, a co-existent 
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staphylococcus and nonGroup A beta 
hemolytic streptococcus failed to re-
spond. We suspect the dose of cepha-
lexin was inadequate in this case, since 
higher serum levels are necessary to in-
hibit many strains of staphylococci. 
In summary, cephalexin was shown 
to produce high serum and mine levels 
when administered by the oral route, 
was well tolerated, and was effective 
against infections caused by susceptible 
organisms. 
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